The Motley Fool··Prosper Junior BakinyEli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition
Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug